CITIC(00267)Nanjing Iron & Steel(600282.SH) is expected to have a net profit attributable to shareholders of approximately 2.867 billion yuan in 2025, representing a year-on-year increase of 26.83%.
Citic Securities (00267) announced the 2025 performance of Nansteel (600282.SH), with operating income of approximately 57.994 billion yuan, a decrease of 6.17% year-on-year; net profit attributable to shareholders of the listed company is approximately 2.867 billion yuan, an increase of 26.83% year-on-year; basic earnings per share is 0.4651 yuan.
CITIC (00267) announced Nanjing Iron & Steel (600282.SH) performance in 2025, with operating income of approximately 57.994 billion yuan, a decrease of 6.17% year-on-year; net profit attributable to shareholders of the listed company is about 2.867 billion yuan, an increase of 26.83% year-on-year; basic earnings per share is 0.4651 yuan.
The announcement stated that the decrease in revenue was mainly due to a year-on-year decrease in the selling prices of steel products during the reporting period.
In 2025, Nanjing Iron & Steel's sales volume of advanced steel materials was 2.8265 million tons, an increase of 8.09% year-on-year, accounting for 30.45% of total steel product sales, an increase of 2.42 percentage points; gross profit margin was 20.88%, an increase of 3.71 percentage points year-on-year; gross profit totaled 3.004 billion yuan, an increase of 20.37% year-on-year, accounting for 48.15% of total gross profit of steel products, an increase of 1.59 percentage points.
In 2026, Nanjing Iron & Steel's main operational objectives are: (1) steel output of 9.78 million tons; (2) achieve operating income of 58.5 billion yuan; (3) estimated additional fixed asset investment in the steel industry of 1.916 billion yuan, fixed asset investment expenditure of 2.999 billion yuan; (4) achieve safety in production.
Related Articles

CHINA GLASS (03300) issued a profit warning, expecting an annual loss of no more than 5.8 billion yuan.

CITIC (00267): Citic Press Corporation (300788.SZ) achieved a net profit attributable to the parent company of 130 million yuan in 2025, representing a year-on-year growth of 9.63%.

CHINARES PHARMA (03320): CHINARES PHARMA plans to list and sell approximately 5.88% of its equity stake in Tianmai Biotechnology.
CHINA GLASS (03300) issued a profit warning, expecting an annual loss of no more than 5.8 billion yuan.

CITIC (00267): Citic Press Corporation (300788.SZ) achieved a net profit attributable to the parent company of 130 million yuan in 2025, representing a year-on-year growth of 9.63%.

CHINARES PHARMA (03320): CHINARES PHARMA plans to list and sell approximately 5.88% of its equity stake in Tianmai Biotechnology.






